Dyskinesia in Parkinson's Disease: Meaning, Symptoms, Risks, and Treatment

What is Dyskinesia? Definition and Context

The word dyskinesia derives from the Greek dys (abnormal) and kinesis (movement). As a general medical term, it refers to any abnormality of voluntary movement. In clinical practice, however, particularly within the context of Parkinson’s disease, it takes on a more specific meaning.

This article follows the definition proposed by the European Parkinson’s Disease Association (EPDA): dyskinesia as a characteristic manifestation of Parkinson’s disease. Specifically, it arises as a side effect of levodopa, which is marketed as Madopar® and Sinemet® among other formulations. Levodopa remains the most widely used and most effective medication for the motor symptoms of Parkinson’s disease.

In this context, dyskinesia describes involuntary, non-intentional, and uncontrollable movements, such as spasms, jerks, twisting motions, or a generalized, fluid restlessness. These movements are not under the patient’s conscious control and cannot be suppressed by an act of will.

What Dyskinesia Is Not: Important Distinctions

To understand dyskinesia clearly, it is essential to distinguish it from other movement abnormalities that may co-exist in Parkinson’s disease:

Tremor

The classic resting tremor of Parkinson’s disease, typically a rhythmic 4–6 Hz oscillation of the hands known as the “pill-rolling” tremor, is a direct manifestation of the disease itself rather than a side effect of medication. Levodopa-induced dyskinesia may also produce shaking-like movements that superficially resemble tremor, but the two have distinct mechanisms and different patterns. Tremor is rhythmic and relatively regular; dyskinesia is typically more flowing, dance-like, and irregular in character.

Dystonia

Dystonia is a movement disorder characterized by sustained or intermittent muscular contractions causing abnormal, often painful postures and repetitive twisting movements. In Parkinson’s disease, dystonia can be a direct symptom of the disease (particularly in younger-onset Parkinson’s) or can occur in the “off” state when medication levels are low. In contrast to dyskinesia’s fluid, dance-like character, dystonic movements are slower, more sustained, contorted, and often painful.

Some patients with Parkinson’s disease experience both dyskinesia and dystonia. Dyskinesia typically occurs as a side effect of medication, while dystonia is usually a symptom of the disease itself. In these individuals, distinguishing between the two can sometimes be clinically challenging.

Tics

Tics are sudden, repetitive, non-rhythmic movements that involve isolated muscle groups. Examples include eye blinking, shoulder shrugging, or throat clearing. They differ from dyskinesia in their stereotyped, repetitive character and their partial suppressibility (tics can often be briefly controlled through voluntary effort, at the cost of building internal tension).

When Does Dyskinesia Develop?

Levodopa-induced dyskinesias typically emerge several years after the initiation of levodopa therapy. On average, this occurs after about 4–6 years of continuous treatment, though the timing varies considerably between individuals. Younger patients (those with early-onset Parkinson’s disease, defined as onset before age 50) are at particular risk and may develop dyskinesias sooner and with greater severity.

The timing and pattern of dyskinesias change over the course of the disease and its treatment, reflecting the progressive loss of dopaminergic neurons and the resulting changes in how the brain responds to dopamine stimulation.

---

Which Parts of the Body Are Affected?

Dyskinesia can affect virtually any part of the body, including the face and neck. However, the most commonly and prominently affected areas are as follows:

• Legs and feet: Often the first area affected in many patients; may manifest as involuntary leg movements, foot rotation, or restless foot tapping
• Arms and hands: Flowing, dance-like movements of the arms; sometimes rapid hand or wrist motions
• Trunk: Oscillating, swaying, or twisting movements of the torso
• Head and neck: Rhythmic or irregular head movements
• Face: Grimacing, involuntary mouth movements, tongue protrusion

In severe cases, dyskinesia may impact internal organ musculature, especially the respiratory muscles. This can lead to irregular breathing patterns and, in very severe instances, respiratory compromise.

The distribution and pattern of dyskinesia differs between patients and changes over time within the same individual, making it a highly heterogeneous phenomenon.

---

How Does Dyskinesia Manifest?

The movements of dyskinesia are characteristically rapid, flowing, and somewhat dance-like, which differs significantly from the slow, sustained contortions of dystonia. Some researchers have described them as resembling a continuous, flowing choreographic motion (a term reflected in the medical synonym “chorea”).

However, dyskinesia presents across a broad spectrum of severity and character:

Mild presentations may include:

• A subtle, continuous nodding or swaying of the head
• Light, involuntary bobbing of a limb
• A sense of internal restlessness or physical agitation that observers may notice before the patient does
• Fine, barely perceptible movements of the fingers or toes

Moderate presentations include:

• Visible, rhythmic or semi-rhythmic movements of the arms or legs that do not completely prevent activity
• Persistent rocking or swaying of the trunk
• Oscillating head movements

Severe presentations involve:

• Large-amplitude, uncontrollable movements of multiple body parts simultaneously
• Movements that interfere significantly with daily activities (eating, writing, walking)
• Falls risk due to balance disruption from trunk or leg dyskinesia
• Social distress due to visibility of the movements

Each patient presents differently in terms of timing, frequency, and severity. For some, dyskinesia is an occasional, barely noticeable nuisance; for others, it is a major disability that profoundly affects independence and quality of life.

Peak-Dose Dyskinesia

Peak-dose dyskinesia is the most common pattern. As the name indicates, this occurs when the plasma concentration of levodopa reaches its maximum level, usually within 1–2 hours after oral administration. At this point, dopamine levels in the striatum (a key component of the basal ganglia) are at their highest, and the dysregulated dopamine receptors that have developed with chronic levodopa exposure produce involuntary movements.

In the context of the so-called “therapeutic window” in Parkinson’s disease management:

• When levodopa levels are too low → the patient is “off” (experiencing Parkinson’s symptoms: rigidity, slowness, tremor)
• When levodopa levels are within the therapeutic range → the patient is “on” (symptom control without dyskinesia)
• When levodopa levels are at their peak → peak-dose dyskinesia may occur

Over years of treatment, as the disease progresses and dopaminergic neurons are further lost, this therapeutic window narrows. As a result, achieving good motor control without dyskinesia becomes increasingly difficult.

Biphasic Dyskinesia

A less common but clinically important pattern is biphasic dyskinesia. In this form, involuntary movements do not occur at peak dose. Instead, they appear at two distinct points in the dose cycle: on the way up, as levodopa levels rise, and on the way down, as levels fall back toward the “off” state. The “on” period itself, when medication is at optimal therapeutic levels, is paradoxically relatively free of dyskinesia.

Biphasic dyskinesia is associated with lower levodopa concentrations and may reflect a different mechanism of receptor sensitization. It is often more difficult to manage than peak-dose dyskinesia because the conventional strategy of reducing the levodopa dose (which would reduce peak-dose dyskinesia) can worsen biphasic dyskinesia by preventing the patient from achieving an adequate “on” state.

---

Causes

The Neurological Basis

The immediate cause of dyskinesia can be located anywhere along the chain of structures linking the brain to the muscle:

• Cerebral cortex
• Basal ganglia (the neural circuits most critically disrupted in Parkinson’s disease and dyskinesia)
• Spinal cord
• Motor neurons
• Peripheral nerves
• Muscles

The Dopaminergic Mechanism of Levodopa-Induced Dyskinesia

In Parkinson’s disease, the progressive degeneration of dopaminergic neurons in the substantia nigra, a nucleus within the basal ganglia, leads to a dramatic reduction in dopamine levels in the striatum. This dopamine deficiency is the primary neurochemical basis of Parkinson’s motor symptoms.

Levodopa (L-DOPA) is the amino acid precursor to dopamine. When taken orally, it crosses the blood-brain barrier and is converted to dopamine in the brain, temporarily restoring dopamine levels and improving motor function. This is why levodopa remains the most effective symptomatic treatment for Parkinson’s disease.

However, with prolonged use, especially at higher doses, the striatum undergoes adaptive changes. These changes occur in response to the repeated, pulsatile stimulation of dopamine receptors.

1. Pulsatile dopamine delivery: Oral levodopa produces fluctuating brain dopamine levels. These fluctuations include peaks and troughs, which correspond to drug absorption and metabolism. As dopaminergic neurons are progressively lost, the striatum loses its natural capacity to buffer these fluctuations (in healthy dopaminergic neurons, dopamine is stored and released in a regulated fashion; with neuronal loss, the brain becomes dependent on exogenous levodopa and highly sensitive to its pharmacokinetic peaks and troughs).

2. Receptor sensitization and synaptic plasticity: Prolonged pulsatile dopaminergic stimulation induces maladaptive changes in the sensitivity and signaling of striatal dopamine receptors. This process is known as receptor supersensitization. These changes alter the normal inhibitory and excitatory circuitry of the basal ganglia in ways that promote involuntary movement.

3. Disruption of basal ganglia circuitry: The basal ganglia, a group of subcortical nuclei including the striatum, globus pallidus, subthalamic nucleus, and substantia nigra, normally function as a regulatory system. This system suppresses unwanted movements and facilitates desired ones. In advanced Parkinson’s disease compounded by levodopa sensitization, this regulatory function is disrupted, and involuntary movements emerge.

The result is a cruel paradox. Levodopa effectively controls the symptoms of Parkinson’s disease, yet its long-term use creates a new and potentially disabling complication: dyskinesia.

Risk Factors for Developing Dyskinesia

Not all patients on levodopa develop dyskinesia, and the severity varies enormously. Established risk factors include:

• Duration of levodopa treatment: The longer the exposure, the higher the cumulative risk
• Dose of levodopa: Higher doses are associated with greater risk
• Age of onset of Parkinson’s disease: Earlier onset (particularly <50 years) is strongly associated with earlier and more severe dyskinesia
• Severity of nigrostriatal degeneration: Greater neuronal loss means less buffering capacity and greater sensitivity to pulsatile stimulation
• Female sex: Women with Parkinson’s disease appear to have a modestly higher risk of dyskinesia, possibly related to differences in levodopa pharmacokinetics

---

Treatment

The management of levodopa-induced dyskinesia requires individualized, nuanced adjustment. No single universal solution exists, so treatment decisions must carefully balance two key priorities: ensuring adequate motor control, which requires sufficient levodopa, and minimizing dyskinesia, which may call for reducing levodopa exposure.

Management options include:

Pharmacological Adjustment of Levodopa Dosing

The simplest first approach is to modify how levodopa is taken:

• Dose fractionation: Dividing the total daily levodopa dose into more frequent, smaller doses helps spread dopamine stimulation more evenly throughout the day. This approach reduces peak concentrations and smooths the troughs, which may decrease both peak-dose dyskinesia and “off” periods. This must be balanced against the practical burden of more frequent medication taking.

• Switching to controlled-release (extended-release) formulations: Levodopa is available in extended-release preparations (e.g., Sinemet CR, or the newer carbidopa/levodopa extended-release capsule Rytary®) that release the drug more slowly and sustainably, producing smoother plasma levels with lower peaks and higher troughs. This can reduce the amplitude of dopamine fluctuations and may decrease dyskinesia severity, though bioavailability differences mean dose adjustments are necessary.

• Continuous levodopa-carbidopa intestinal gel (LCIG/Duodopa®): In advanced Parkinson’s disease with severe motor fluctuations, continuous intraduodenal infusion of levodopa-carbidopa gel through a surgically placed jejunal tube provides the most stable possible levodopa delivery, minimizing the pulsatile stimulation that drives dyskinesia. This is a highly effective but invasive option reserved for selected patients.

Amantadine

Amantadine was originally developed as an antiviral agent but was serendipitously discovered to have beneficial effects in Parkinson’s disease. It is currently the only medication with well-established evidence for reducing levodopa-induced dyskinesia without significantly worsening motor control.

Amantadine acts primarily as an NMDA (N-methyl-D-aspartate) glutamate receptor antagonist. Glutamatergic overactivity in the basal ganglia is believed to contribute to dyskinesia through mechanisms complementary to dopaminergic sensitization, and amantadine’s blockade of NMDA receptors helps normalize this overactivity.

Side effects include ankle swelling, livedo reticularis (a mottled skin discoloration), confusion (particularly in older patients), and hallucinationsa. A newer extended-release formulation of amantadine (ADS-5102 / Gocovri®) has been specifically approved for treating levodopa-induced dyskinesia and has demonstrated efficacy in clinical trials (Pahwa et al., 2017).

Modifying Other Antiparkinsonian Medications

• MAO-B inhibitors (rasagiline, selegiline): By inhibiting the enzyme that breaks down dopamine, these agents can prolong and smooth the dopaminergic effect of levodopa, potentially allowing levodopa dose reduction.
• COMT inhibitors (entacapone, tolcapone, opicapone): Reduce peripheral metabolism of levodopa to its inactive metabolite, increasing the proportion that reaches the brain. This allows levodopa dose reduction while maintaining efficacy, potentially reducing peak concentrations and dyskinesia.
• Dopamine agonists (pramipexole, ropinirole, rotigotine): Provide more continuous, non-pulsatile dopamine receptor stimulation than levodopa and are associated with a lower risk of dyskinesia. They may allow levodopa dose reduction when added to the regimen.

Deep Brain Stimulation (DBS)

Deep brain stimulation is a surgical treatment in which thin electrodes are implanted into specific brain targets, most commonly the subthalamic nucleus (STN) or the globus pallidus internus (GPi), and connected to a pulse generator (similar to a cardiac pacemaker) implanted under the skin of the chest. Continuous electrical stimulation of these targets modulates the abnormal basal ganglia circuitry, simultaneously improving motor control and allowing significant reductions in levodopa dose.

DBS is highly effective for both motor fluctuations and dyskinesia in appropriately selected patients. GPi stimulation directly reduces dyskinesia even without levodopa dose reduction; STN stimulation primarily allows levodopa reduction, which indirectly reduces dyskinesia.

DBS is not appropriate for all patients; candidate selection requires careful neurological, neuropsychological, and general medical assessment. It is generally reserved for patients with advanced Parkinson’s disease, established dopaminergic responsiveness, and motor fluctuations/dyskinesias that are not adequately controlled through pharmacological optimization.

Diet and Nutrition

Dietary management plays a meaningful supporting role in dyskinesia management, though it does not replace pharmacological approaches.

The key dietary consideration is the interaction between dietary protein and levodopa absorption. Levodopa is an amino acid and is absorbed from the intestine via the same transport system as large neutral amino acids (phenylalanine, tyrosine, valine, isoleucine, leucine, tryptophan). When dietary protein is consumed simultaneously with levodopa, competition for this transport system reduces levodopa absorption and delays its entry into the brain. This can potentially prolong “off” periods and cause unpredictable motor fluctuations.

Practical strategies:

• Take levodopa at least 30 minutes before meals (or 60–90 minutes before protein-containing meals) to allow absorption before dietary amino acids arrive in the small intestine
• Redistribute protein intake to later in the day: Some patients benefit from consuming the majority of their daily protein intake at the evening meal, allowing more predictable and effective levodopa action during the daytime hours of peak activity
• Avoid dramatically low-protein diets: Protein is essential for health. Extremely protein-restricted diets are neither safe nor necessary. The goal is timing, not elimination.
• Work with a registered dietitian or clinical nutritionist familiar with Parkinson’s disease. Dietary adjustments that affect levodopa pharmacokinetics require individualized, supervised planning to ensure nutritional adequacy.

Other nutritional considerations: adequate hydration (which affects gastric emptying and therefore drug absorption), dietary fiber (constipation is extremely common in Parkinson’s disease and can delay levodopa absorption), and maintaining a healthy body weight.

Physical Activity and Rest

Managing Acute Dyskinesia Episodes

During a severe episode of dyskinesia, especially if the movements are causing distress or are socially disruptive, the following measures can help:

• Lie down on a bed or firm surface, preferably on one side: The lying position reduces the mechanical demands on the musculature and often reduces the amplitude of dyskinetic movements.
• Breathe slowly and deeply: Focusing on controlled, diaphragmatic breathing activates the parasympathetic nervous system and promotes muscular relaxation.
• Do not attempt to actively suppress the movements: Resisting dyskinesia requires muscular effort and mental concentration that tends to worsen the movements. The opposite approach, complete acceptance and relaxation, is more effective.
• Remove yourself from situations where social visibility is causing anxiety: Stress and anxiety can worsen dyskinesia (see below).

Regular Exercise

Beyond acute management, regular physical exercise is consistently recommended for patients with Parkinson’s disease, including those with dyskinesia:

• Aerobic exercise, strength training, balance training, dancing (particularly structured programs such as tango therapy), and swimming have all demonstrated benefits in Parkinson’s disease research
• Exercise improves motor function, balance, gait, and quality of life. Some evidence also suggests that regular physical activity may have neuroprotective effects and modify disease progression.
• Exercise timing should account for medication dosing: scheduling exercise during periods of good “on” time reduces the risk of falls from dyskinesia or “off”-state rigidity

Stress Management

Stress has a well-established, bidirectional relationship with dyskinesia in Parkinson’s disease:

• Psychological stress activates the sympathetic nervous system and increases cortisol levels, which can directly exacerbate dyskinetic movements.
• The social visibility and unpredictability of dyskinesia itself causes significant psychological stress, creating a vicious cycle.

Practical stress management strategies:

• Plan demanding or social activities during periods of optimal medication effect; most patients develop, over time, a good intuitive sense of when their medication is providing its best effect. Scheduling important meetings, social engagements, or demanding physical tasks during these windows reduces both motor difficulty and associated stress.
• Mindfulness and relaxation techniques: Deep breathing exercises, progressive muscle relaxation, meditation, and yoga have demonstrated stress-reducing effects and may indirectly benefit dyskinesia management.
• Psychological support: Living with Parkinson’s disease and its complications is psychologically challenging. Cognitive-behavioral therapy (CBT) and support groups provide valuable tools for managing the emotional burden of chronic disease.
• Ensure adequate sleep: Sleep disturbance is extremely common in Parkinson’s disease and profoundly affects symptom management. Prioritizing good sleep hygiene and treating specific sleep disorders (such as REM sleep behavior disorder, which is particularly common in Parkinson’s) is an important component of overall care.

---

Tardive Dyskinesia: A Related but Distinct Condition

The term “dyskinesia” is occasionally used in clinical contexts beyond Parkinson’s disease, and it is important to understand the relationship between different forms.

Tardive dyskinesia (TD) is formally defined in the medical literature as “a syndrome comprising a constellation of iatrogenic movement disorders caused by dopamine receptor antagonism”. In simpler terms, it is a group of involuntary movement disorders caused by medications that block dopamine activity, particularly antipsychotic drugs (also called neuroleptics).

This is the opposite pharmacological mechanism to levodopa-induced dyskinesia:

Antipsychotic medications, including older first-generation agents (haloperidol, chlorpromazine) and some second-generation agents (risperidone, olanzapine, aripiprazole), block striatal dopamine D2 receptors. When used for the treatment of schizophrenia, bipolar disorder, depression, or even for anti-nausea purposes over extended periods, this dopamine receptor blockade triggers compensatory receptor supersensitization, which eventually produces the involuntary movements of tardive dyskinesia.

Clinical Features of Tardive Dyskinesia

Tardive dyskinesia predominantly affects the muscles of the face, particularly:

• Orobuccolingual movements: Repetitive tongue protrusion, lip smacking, chewing movements, puckering
• Facial grimacing: Irregular facial muscle contractions

However, it can also involve:

• Trunk: Rocking, swaying, shifting movements
• Hands and feet: Repetitive finger movements, piano-playing motions, foot flexion and extension
• Respiratory muscles: Irregular breathing patterns (rare)

The movements are characteristically stereotyped and repetitive, with the same movements occurring in the same pattern, distinguishing them somewhat from the more flowing, variable character of levodopa-induced dyskinesia.

Diagnosis

The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) defines tardive dyskinesia as a movement disorder induced by medications that persists despite discontinuation of or reduction in the causative drug. Specifically, symptoms must be present for at least one month after stopping the medication to meet DSM-5 criteria for tardive dyskinesia.

This persistence distinguishes tardigve dyskinesia from withdrawal-emergent dyskinesia, which is a brief, transient movement disorder that appears immediately after antipsychotic discontinuation and resolves within weeks.

Treatment of Tardive Dyskinesia

• Discontinuation or dose reduction of the causative medication (when psychiatrically feasible and safe): In many cases, dyskinesia improves or resolves within weeks to months after stopping the antipsychotic. However, this approach may not always be possible due to the patient’s psychiatric needs.
• Switching to a lower-risk antipsychotic: Second-generation antipsychotics (particularly clozapine and quetiapine) carry a lower risk of tardive dyskinesia than first-generation agents; switching may allow some improvement.
• VMAT2 inhibitors: Valbenazine (Ingrezza®) and deutetrabenazine (Austedo®) are specifically FDA-approved for the treatment of tardive dyskinesia. They work by depleting presynaptic dopamine stores, reducing dopaminergic transmission and thereby decreasing dyskinetic movements. Both have demonstrated efficacy in randomized controlled trials.
• Amantadine: As in levodopa-induced dyskinesia, amantadine may provide some benefit through NMDA receptor antagonism.
• Clonazepam: May reduce the distress and severity of movements in some patients through GABAergic mechanisms.

The Terminological Summary

To clarify the precise terminology:

• Dyskinesia (general term): Any involuntary, abnormal movement.
• Levodopa-induced dyskinesia (LID): The most common specific form, caused by long-term levodopa therapy in Parkinson’s disease. When people with Parkinson’s speak of “dyskinesia”, this is almost always what they mean.
• Tardive dyskinesia (TD): Caused by prolonged dopamine receptor antagonism from antipsychotic medications. It is a distinct condition with a different pharmacological mechanism, clinical pattern, and management approach.

---

Bibliography and Sources

• European Parkinson’s Disease Association (EPDA). Dyskinesia. https://www.epda.eu.com/

• Healthline. Dyskinesia: Types, causes, and treatment. https://www.healthline.com/health/dyskinesia

• Bhidayasiri, R., & Fahn, S. (2013). Tardive Dyskinesia. In StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK448207/

• Pahwa, R., Tanner, C.M., Hauser, R.A., et al. (2017). ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID 3): A randomized clinical trial. JAMA Neurology, 74(8), 941–949.

• Cenci, M.A. (2014). Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Frontiers in Neurology, 5, 242.

• Bastide, M.F., Meissner, W.G., Picconi, B., et al. (2015). Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Progress in Neurobiology, 132, 96–168.

• Vijayakumar, D., & Jankovic, J. (2016). Drug-induced dyskinesia, part 2: Treatment of tardive dyskinesia. Drugs, 76(7), 779–787.

• American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Washington, DC: APA Publishing.

• Connolly, B.S., & Lang, A.E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA, 311(16), 1670–1683.

• Deuschl, G., Schade-Brittinger, C., Krack, P., et al. (2006). A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine, 355(9), 896–908.